Bristol Myers Squibb to present phase 3 Zenbexus multiple myeloma data at ASH 2026
BMY•Bristol Myers Squibb will present hematology trial data at the ASH meeting in New Orleans, December 12-15, 2026, including phase 3 Zenbexus-based combination results in multiple myeloma.
1. Trial data planned
Bristol Myers Squibb plans to present hematology trial data at the ASH meeting in New Orleans, December 12-15, 2026. Phase 3 EXCALIBER-RRMM results will assess disease progression and residual disease with a Zenbexus-based combination in relapsed or refractory multiple myeloma.
2. Other studies
A five-year Phase 3 TRANSFORM follow-up will highlight Breyanzi's potential for cure in second-line relapsed or refractory large B-cell lymphoma. Early-stage results will evaluate the safety and efficacy of dual-targeted CAR T therapy tunlucabtagene autoleucel in relapsed or refractory multiple myeloma.




